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Abstract 
Deep generative models have shown the ability to devise both valid and novel chemistry, which could significantly 
accelerate the identification of bioactive compounds. Many current models, however, use molecular descriptors or 
ligand-based predictive methods to guide molecule generation towards a desirable property space. This restricts their 
application to relatively data-rich targets, neglecting those where little data is available to sufficiently train a predictor. 
Moreover, ligand-based approaches often bias molecule generation towards previously established chemical space, 
thereby limiting their ability to identify truly novel chemotypes. In this work, we assess the ability of using molecular 
docking via Glide—a structure-based approach—as a scoring function to guide the deep generative model REIN-
VENT and compare model performance and behaviour to a ligand-based scoring function. Additionally, we modify 
the previously published MOSES benchmarking dataset to remove any induced bias towards non-protonatable 
groups. We also propose a new metric to measure dataset diversity, which is less confounded by the distribution of 
heavy atom count than the commonly used internal diversity metric. With respect to the main findings, we found 
that when optimizing the docking score against DRD2, the model improves predicted ligand affinity beyond that 
of known DRD2 active molecules. In addition, generated molecules occupy complementary chemical and physico-
chemical space compared to the ligand-based approach, and novel physicochemical space compared to known 
DRD2 active molecules. Furthermore, the structure-based approach learns to generate molecules that satisfy crucial 
residue interactions, which is information only available when taking protein structure into account. Overall, this work 
demonstrates the advantage of using molecular docking to guide de novo molecule generation over ligand-based 
predictors with respect to predicted affinity, novelty, and the ability to identify key interactions between ligand and 
protein target. Practically, this approach has applications in early hit generation campaigns to enrich a virtual library 
towards a particular target, and also in novelty-focused projects, where de novo molecule generation either has no 
prior ligand knowledge available or should not be biased by it.
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Introduction
Generative models are a class of machine learning algo-
rithms that model the distribution of training data, such 
that new data instances can be generated that resemble 
the training data distribution. These models have been 
successfully applied to de novo molecule generation, 
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namely deep generative models which utilise deep neu-
ral networks [1–3]. Generative models for de novo mol-
ecule generation can generate valid and novel chemical 
structures [4] by either learning from a dataset of exam-
ple molecules or learning appropriate actions to take 
given a set of symbolic rules. Although these models vary 
greatly in method [5], they can usually be categorised by 
four common architectures/approaches: (1) Language 
models (such as [6–8]) which require a chemical lan-
guage (e.g., SMILES [9]) to represent molecular struc-
ture and subsequently learn the probability of a symbol 
in a sequence given all previously observed symbols; (2) 
Autoencoders (such as [10–12]) which use an encoder 
and decoder network to embed molecules into a fixed 
size latent space which can then be traversed to generate 
de novo molecules; (3) Generative adversarial networks 
(such as [13–15]) which use a generator and discrimi-
nator neural network to transform random noise into a 
distribution indistinguishable from real data and (4) Pure 
reinforcement learning (such as [16–18]) which uses 
neural networks to learn which actions to take given a set 
of molecule building rules.
The common goal of de novo molecule generation is 
to generate molecules within a desired property space, 
which in turn is often defined using ligand-based objec-
tives or scoring functions. Examples include using known 
bioactive molecules as training data to bias generation 
towards a similar property space (e.g. biased training or 
fine-tuning) [2, 6, 19], or using machine learning mod-
els trained on known bioactive molecules to predict de 
novo molecule bioactivity (e.g. quantitative structure–
activity relationship (QSAR) models). Generative models 
can then be optimized to maximize this predicted value 
e.g. using reinforcement learning [7, 8, 20, 21], Bayesian 
optimization [22] or particle swarm optimization [23]. 
Hence, a multitude of generative model methods exist, 
that can use none, one or multiple QSAR models or other 
external scoring functions to evaluate de novo molecules. 
Furthermore, generative models can then be optimized 
by one of several possible optimization algorithms. In 
drug discovery, most combinations of these methods rely 
on ligand data to optimize towards bioactivity.
However, ligand-based scoring functions (e.g. QSAR 
models) have inherent limitations. Firstly, machine learn-
ing models are restricted by their applicability domain 
i.e. they perform well on ‘in-distribution’ data but strug-
gle to extrapolate to ‘out-of-distribution’ data, which is 
often poorly accounted for in model validation [24, 25]. 
This means that models will score molecules similar to 
those observed in the training data more accurately [26]. 
In fact, Renz et al. [27] recently demonstrated that deep 
generative models optimizing QSAR model predictions 
biased molecule generation towards these QSAR models 
so much that generated molecules were no longer pre-
dicted as active by control QSAR models, which were 
either initialized with a different seed or trained on a 
different data split. This showed that ligand-based scor-
ing functions can subsequently lead to biased molecule 
generation, optimizing just one of many possible desir-
able property spaces—the one most similar to training 
data and conforming to particular model parameters and 
hyperparameters. This is very likely a reason for the lack 
of diversity (and inability to access truly novel chemical 
space) seen in deep generative models [28, 29]. This bias 
towards specific training data (either directly via fine-
tuning or indirectly via ligand-based scoring functions) 
therefore restricts the novelty aspect of such ligand-
guided deep generative models in practice and limits 
their exploration of novel chemical space. This is a seri-
ous drawback from both an intellectual property and 
discovery perspective; for example, during lead optimiza-
tion the inability to discover novel chemistry can lead to 
property ‘dead zones’, where it can be difficult to optimize 
certain properties of a particular lead series further. This 
lack of novelty observed in current deep generative mod-
els has also been commented on in the literature [30]. 
Hence, the choice and implementation of ligand-based 
approaches can have a significant impact on de novo 
molecule generation.
From a practical perspective, ligand-based scoring 
functions also require large enough amounts of anno-
tated ligand data to sufficiently train a machine learning 
model in the first instance, which typically restricts the 
use of machine learning models to data-rich areas. How-
ever, many key drug discovery objectives, such as being 
first-in-class with respect to a novel target, are typically 
ligand data poor. This, therefore, even conceptually pre-
vents the application of ligand-guided deep generative 
models in this situation.
In this work, we explored the idea that structure-based 
scoring functions, as exemplified by molecular dock-
ing, may mitigate some of the limitations observed with 
ligand-based scoring functions. Molecular docking is a 
physics-based approach that uses the crystal structure 
(or in the absence of that a homology model) of a pro-
tein to estimate both the pose and free energy binding of 
a ligand [31–34]. Although the resulting free energy score 
is notoriously inaccurate [35, 36] and the performance of 
these scoring functions can be highly target-dependent 
[37], molecular docking consistently results in the early 
enrichment of known active molecules in virtual librar-
ies compared to random [35] and is a generally-applied 
computational ligand design method in pharmaceutical 
research today.
The principal advantage of the physics-based nature 
of molecular docking is that it is not restricted to the 
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chemical space of existing bioactive training data from 
the ligand side. Provided a scoring function achieves 
enrichment of bioactive compounds against a protein tar-
get (which can be established on existing datasets where 
data is available, but where otherwise estimates can be 
made based on the character of the binding pocket and 
protein type [38, 39]), then the chemical space to be 
scored can be greatly expanded, beyond chemistry and 
chemotypes present in any ligand-based training dataset. 
As structural input, either experimentally resolved struc-
tures or homology models can be employed and given 
the increasing numbers of structures available (which 
increases by about 10,000 per year [40]) and develop-
ment of protein structure prediction technology [41], this 
renders this approach applicable to an increasingly wide 
range of protein targets.
In concrete terms regarding the methods employed, 
we utilized the REINVENT [7] algorithm that has evi-
denced competitive performance with respect to the cov-
erage of de novo chemical space [42]. REINVENT uses 
a language-based generative model that takes in molecu-
lar SMILES as input (one-hot encoded) and a recurrent-
neural network to predict the probability of the next 
SMILES symbol given all previously sampled SMILES 
symbols in a sequence. REINVENT uses reinforcement 
learning to optimize molecule generation to maximize 
a reward provided by an external scoring function (for 
further details see “Methods”). We used this approach 
to optimize de novo molecules to minimize the docking 
score returned by Glide [32]. To understand the differ-
ences between ligand-based and structure-based scoring 
functions, we compare the resulting de novo molecules 
to those generated by a model optimized to maximize 
the predicted probability of activity by a support vector 
machine (SVM) scoring function. This work could also 
be conducted using open-source docking software (e.g. 
Smina [43]) which we also provide available code for (see 
“Availability of data and materials”).
As a case study, we chose affinity for Dopamine Recep-
tor D2 (DRD2). This receptor has a wealth of associated 
ligand bioactivity data available, and it has been com-
monly used in deep generative model publications before 
[7, 21, 22, 29, 44], thereby allowing any further com-
parison to different methods. DRD2 also has a publicly 
available X-ray crystal structure [45] in complex with 
Risperidone, thereby allowing use of molecular dock-
ing without the requirement of generating a homology 
model. More generally, G protein-coupled receptors 
(GPCRs)—including DRD2—are the most commonly tar-
geted protein class accounting for approximately 34% of 
all FDA approved drugs [46]. However, they remain some 
of the most difficult proteins to crystallise. Although 
more structures are released every year [40], which offers 
an ever increasing opportunity to utilise structure-based 
design [47].
To our knowledge, few previous studies exist which 
have incorporated structural data into deep generative 
model scoring functions, compared to the ligand-based 
counterpart. Firstly, Ghanakota et al. [48] combined high 
throughput free energy perturbation (FEP) with REIN-
VENT to identify potential CDK2 inhibitors. To achieve 
this, they trained an AutoQSAR model [49] on a subset 
of 1,000 enumerated analogues of a potent inhibitor with 
the corresponding FEP predictions, which was subse-
quently used as the REINVENT scoring function. The 
authors observed 1.5-fold enrichment selecting com-
pounds with activity below 10 nM, compared to select-
ing enumerated analogues using the AutoQSAR model 
alone. Secondly, Li et  al. [50] trained a recurrent neural 
network on known kinase CDK4 inhibitors and fine-
tuned the network by training on a selection of generated 
molecules screened using docking. This was validated 
experimentally, with one out of nine tested molecules 
found to be active against the target (57.8% inhibition at 
10 µM). Thirdly, Xu et  al. [51] similarly used molecular 
docking to guide ligand selection in the latent space of a 
variational autoencoder towards CDK2 predicted activ-
ity, resulting in the recovery of a known CDK2 inhibi-
tor and several molecules containing substructures of 
known CDK2 inhibitors. Cieplinksi et al. [52] evidenced 
that CVAE [10] and GVAE [53] were unable to gener-
ate molecules with optimized Smina [43] docking scores 
due to the inaccurate prediction of said docking score, 
which is used to guide de novo sampling in the respec-
tive methods. Although, the authors propose a docking 
benchmark on which REINVENT outperforms the above 
methods and baselines of both random and known active 
molecules [54]. Lastly, Boitreaud et al. [55] recently used 
a novel sampling approach combined with a graph to 
SELFIES [56] variational autoencoder, where the authors 
demonstrated the ability to optimize the Vina [34] dock-
ing score against Dopamine Receptor D3, while main-
taining chemical diversity.
Notable contrasts in our approach compared to the 
above approaches include: (1) We only require structure 
data, enabling the search of a much larger chemical space 
compared to the use of ligand data as in [50]. (2) We uti-
lize a recurrent neural network with reinforcement learn-
ing as opposed to a variational autoencoder with Bayesian 
optimization as in [55]. (3) We directly use a physics-
based scoring function (i.e. molecular docking) to obtain 
scores during the generative model training process, as 
opposed to predicting the outcome of said function via 
machine learning as in [48, 52]. (4) In our approach, the 
model actively learns the conditional probability distribu-
tion of SMILES symbols that are associated with better 
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docking scores and as such variable size distributions can 
be sampled (up to billions [57]) of molecules, as opposed 
to sampling a finite latent space as in [51]. Therefore, our 
approach presented here differs to previously published 
approaches conceptually.
Methods
Figure 1 depicts the approach taken for the comparison 
of a structure- and ligand-based scoring functions in a 
deep generative model setting undertaken in this work. 
We (1) first removed known DRD2 actives (according 
to the ExCAPE-DB [58]) from the MOSES curated [4] 
ZINC [59] database of small drug-like molecules for use 
as training data. We then utilized the REINVENT frame-
work [7] as a deep generative model. This framework 
consists of two recurrent neural networks—a Prior and 
an Agent. The Prior (2) is trained to learn the conditional 
probability distribution of symbols in one-hot encoded 
SMILES, in this case, a set of SMILES from the previously 
described ZINC training data. The Agent is then initial-
ized (3) as an exact copy of the Prior. The scoring func-
tions (4) used in this work either (4a) utilized structural 
data from the PBD [40] and the docking program Glide, 
or (4b) ligand data extracted from ExCAPE-DB [58] to 
build an SVM-based bioactivity model [7] to score mol-
ecules that have been generated de novo. The agent then 
samples de novo SMILES strings which are subsequently 
evaluated by the scoring function (5), and the Agent is 
updated via reinforcement learning to optimize either the 
docking score (5a) or the predicted probability of activ-
ity (5b). One unique aspect of REINVENT is the use of 
the Prior network to evaluate the likelihood of Agent de 
novo molecules being sampled from it, and this likeli-
hood is used within the reward term used to update the 
Agent. This acts to both regularize the Agent to prevent 
overfitting, but also to ensure that the Agent does not 
forget the underlying chemical principles learned from 
the Prior training dataset. For more detail about REIN-
VENT the reader is referred to the original publication 
[7]. Finally (6), we evaluated both model behaviour dur-
ing Agent training and properties of de novo molecules 
with respect to several different quantitative, chemical 
and structural aspects.
Datasets
The dataset used to train the Prior network was modi-
fied from the curation described by MOSES [4], in 
which the authors extracted molecules as SMILES 
from the ZINC15 database [59]. In short, molecules 
were selected to adhere to the following rules: molecu-
lar weight between 250–350 Da; number of rotatable 
bonds not greater than 8; XlogP [60] not greater than 
3.5; no charged atoms; no atoms besides C, N, S, O, F, Cl, 
Br, H; no cycles larger than 8 members; custom medici-
nal chemistry filters [61, 62]; and finally PAINS filters 
[63] were applied. We deviate from this curation by first 
Fig. 1 Schematic of this work including data sources (blue), scoring functions (orange), the deep generative model framework REINVENT [7] (grey). 
Main steps are (1) removing known DRD2 active molecules from the ZINC training data; (2) Training the Prior model on drug-like molecules from 
ZINC; (3) Initializing the Agents as a copy of the Prior; (4) Preparing the scoring functions to evaluate de novo molecules; (5) Iteratively training both 
Agents via reinforcement learning; and (6) evaluating the structure- and ligand-based approach with respect to different quantitative, chemical and 
structural aspects of the generated molecules
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allowing charged atoms and then neutralizing protonat-
able groups. This was achieved by modifying the MOSES 
pipeline, implemented using RDKit [64], to remove the 
filter that checks for formal charge on atoms and instead 
add/remove protons to neutralize atoms where possible 
[65]. As a result, the training split contains 2,454,087 
molecules as opposed to 1,584,664 described in the pub-
lication [4]. The authors rationalized the charge filter as 
such, “we removed charged molecules to avoid ambigu-
ity with tautomer’s and pH conditions. Note that in the 
initial set of molecules, functional groups were present 
in both ionized and unionized forms”. However, given 
the nature of molecule generation conditional upon the 
rest of the molecule (or more specifically the sequence) 
using RNNs used in this work, we instead hypothesize 
that this filter could remove potentially relevant chemical 
structures in which the ‘functional group—whole struc-
ture’ conditional relationship may not be duplicated. We 
further find that only ~ 6500 charged variants are also 
present in the neutral form in the ZINC15 subset out of 
the ~ 870,000 removed due to the charge filter. This may 
further lead to a bias towards non-protonatable chemical 
structures which are crucial for aminergic receptors as 
used in this work, as aminergic receptors typically require 
an ionic interaction with a conserved aspartic acid resi-
due in the orthosteric site (Ballesteros-Weinstein:  D3.32, 
GPCRdb:  D3x32) [66, 67]. To further require the deep 
generative model to explore novel chemical space, we 
also removed any canonical SMILES that matched the 
canonical SMILES of any known DRD2 active molecules 
extracted from the ExCAPE-DB [58] where canonical 
SMILES were generated using RDKit [64] for both sets. 
This resulted in a training set of 2,454,048 canonical 
SMILES.
In order to generate a set of bioactive compounds 
with known DRD2 activity we extracted molecules 
from ExCAPE-DB [58]. ExCAPE-DB is a curation of 
ChEMBL20 [68] and PubChem [69] data that classifies 
molecules with a measured dose–response value equal 
to or lower than 10 μM as active, and with higher than 
10 μM (or those which were labelled inactive in the origi-
nal sources) as inactive. This resulted in 4613 active and 
343,028 inactive molecules against human DRD2. How-
ever, as it may be unreasonable to expect the generative 
model to generate molecules outside the property space 
on which it was trained, we also apply the same filter-
ing as previously described to create another subset 
labelled ‘in’. In addition, for use as a reference baseline 
a set of random molecules with the same filters applied 
were extracted from ChEMBL26 [68]. Resulting in the 
following subsets (of size): Active_all (4613), Active_in 
(396), Inactive_all (10,000), Inactive_in (10,000), Random 
(10,000).
The DRD2 X-ray crystal structure 6CM4 from the PDB 
[40] was used as the protein structure for docking.
Reinvent
The training data described in Datasets was subject to 
further filtering in accordance with the REINVENT pipe-
line [7] to standardize SMILES input, tokenize SMILES 
symbols and construct a vocabulary for one-hot encod-
ing. This filtering resulted in 2,453,916 unique, non-
isomeric (stereochemistry removed) SMILES that was 
subsequently used to train the Prior network for a total 
of 5 epochs with a batch size of 128 using the Adam opti-
mizer [70] with a learning rate of 0.001. The Agent was 
then trained for 3000 steps using a batch size of 64 and 
the Adam optimizer with a learning rate of 0.0005 and a 
value for the scalar coefficient (σ) of 60. These hyperpa-
rameters were used as recommended by the publication 
[7] and not explored further. All neural network training 
was conducted on an NVIDIA  RTX2080Ti GPU.
Scoring functions
A ligand-based scoring function was used as a baseline. 
We used the SVM model previously published by Olive-
crona et al. [7] trained on 7218 active and 100,000 inac-
tive DRD2 molecules, which were also extracted from 
ExCAPE-DB [58]. Note that this figure differs from 
the human DRD2 bioactives we used for evaluation 
described in Datasets for the current work. It is likely that 
the authors did not filter bioactive molecules by species 
(as it stands this would result in 7919 active DRD2 mol-
ecules without further processing [58]), which however is 
particularly important in the current work due to the use 
of the human ortholog of DRD2 for docking, and hence 
we have paid particular attention to this here. The result-
ing SVM predicts the uncalibrated probability of a mol-
ecule to be active against DRD2.
The structure-based scoring function used protein–
ligand docking. The DRD2 crystal structure was prepared 
using the Schrodinger Protein Preparation Wizard [71] 
using default parameters i.e. we added hydrogens, proto-
nated non-residue molecules (e.g. ligand, cofactors), at pH 
7 ± 2 using Epik [72], optimized hydrogen bond assignment 
at pH 7 using PROPKA [73] and minimized the structure 
using the OPLS3e force field [74]. Any waters, cofactors, or 
crystallisation artefacts (e.g., oleic acid) were removed from 
the structure. A grid was defined using the centroid of the 
co-crystallised ligand Risperidone as the centre. From the 
ligand side, before docking, molecules were prepared using 
LigPrep [75], enumerating unspecified stereocentres, tau-
tomers and protonation states (using Epik [72]). Up to 8 
variants were prepared per molecule based on a pH range 
of 7 ± 1 and minimised using the OPLS3e force field. Each 
molecule and any respective variants were then docked 
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using Glide standard precision (GlideScore-SP [32]) with 
default settings, flexible ligand sampling, standard preci-
sion with Epik state penalties, post-docking minimization 
of five poses and final output of the single best scoring pose. 
For molecules where more than a single variant exists, the 
variant with the lowest (best) docking score was chosen. To 
make this task more computationally tractable, we used a 
Python script that parallelized the docking protocol across 
a compute cluster using the python library Dask [76]. Using 
between 36 and 50 CPUs, the wall time required for 3000 
iterations was approximately 7 days, based on an average 
scoring time of 3 min per 64 molecules (including mol-
ecule preparation and up to 512 individual docking runs for 
respective variants).
Retrospective validation of docking protocol and scoring 
functions
In the REINVENT study [6] the authors evaluated the per-
formance of the SVM model on an undisclosed held-out 
test set, resulting in an accuracy of 98%, precision of 97% 
and recall of 82%.
To also evaluate the performance of the docking proto-
col, all 4613 known DRD2 active molecules and a random 
subset of 10,000 DRD2 inactive molecules were docked. 
The performance of classification into either active or inac-
tive molecules at various docking score thresholds was 
then investigated (see Additional file 1: Figure S1) accord-
ing to classification accuracy, precision, and recall (which 
can be calculated using the equations defined below and 
the number of true positives (TP), true negatives (TN), false 
positives (FP) and false negatives (FN)). A docking score 
of − 7.5 resulted in highest overall accuracy of about 76%. 
By decreasing the threshold to − 8.5 (i.e., a more stringent 
criterion for selecting active molecules), a higher precision 
of approximately 82% is achieved, although at lower accu-
racy of about 74% and lower recall of about 12%. However, 
the latter more stringent threshold might still be a more 
favourable one to use in practice, given that confidence in 
positive predictions of active compounds is often more rel-
evant than missing some active compounds (of which there 
are many) due to low recall. It should be remembered that 
the performance of the scoring function was not an objec-
tive in its own right (given that retrospective evaluations 
naturally favour ligand-based methods due to analogue 
bias in databases etc. [77]), but rather to ensure general 
suitability for the desired purpose of selecting active com-
pounds in this step.
Accuracy =
TP + TN
TP + FP + TN + TN
Model performance and diversity metrics
Several metrics were used to assess generative model 
performance, as used in GuacaMol [78] and MOSES [4] 
(see Additional file 1).
In particular, we propose a new metric to meas-
ure the diversity of de novo compounds which we call 
sphere exclusion diversity (SEDiv). SEDiv is the fraction 
of diverse compounds selected using the sphere exclu-
sion algorithm [79] with a sphere radius set to 0.65 
Tanimoto distance of Morgan fingerprints (radius = 2, 
nBits = 1024), using the algorithm implemented by 
Roger Sayle in RDKit [64, 80]. We interpret this as the 
minimum fraction of the dataset required to explain the 
chemical diversity in the context of bioactivity. As a set 
distance threshold of 0.65 (i.e., Tanimoto similarity of 
0.35 or above) broadly correlates to an 80–85% probabil-
ity of belonging to the same bioactivity class [80].
As opposed to internal diversity (see Additional file 1), 
we believe the interpretation of this metric to be more 
meaningful. As the internal diversity can be difficult to 
interpret due to the double average losing the notion of 
the underlying distribution, as well as the confounding 
effect of heavy atom count on Tanimoto similarity [81]. 
To investigate this further, we subset ChEMBL28 [82] 
to only include molecules with 5–50 heavy atoms and 
randomly sampled 500 molecules either side of a heavy 
atom threshold, for thresholds 10–45 in increments of 1 
(with 10 repeats per threshold)—to mimic datasets with 
different proportions of smaller/larger molecules. There 
is a clear decrease in internal diversity with an increase 
in mean number of heavy atoms in accordance with the 
hypothesized confounding effect [81] (see Additional 
file  1: Figure S2a). On the other hand, sphere exclusion 
diversity shows a similar trend to the count of molecules 
per heavy atom bin (see Additional file 1: Figure S2b).
To investigate the difference between SEDiv and inter-
nal diversity further, we calculate these two metrics on 
random subsets of different libraries (Fig.  2): enumer-
ated virtual libraries of stable molecules up to 17 and 
13 heavy atoms (GDB17 [83], GDB13 [84]), character-
ised molecules with varying bioactivities (ChEMBL28 
[82]), a synthetically accessible diversity orientated vir-
tual library (Enamine diverse [85]), synthetically acces-
sible targeted virtual libraries (Enamine GPCR and 
Enamine Kinase [86]) and characterised molecules with 
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(ChEMBL28 Family A GPCRs and ChEMBL28 Kinases) 
and single targets (ChEMBL28 HERG, ChEMBL28 
EGFR and ChEMBL28 DRD2). All datasets were simi-
larly processed to neutralize molecules and retain only 
those with a molecular weight less than 500 Da, to 
ensure a similar ‘drug-like’ chemical space. Most nota-
bly, internal diversity measures GDB13 as more diverse 
than GDB17—which contradicts chemical intuition, but 
further confers with hypothesized confounding effects 
[81]. Furthermore, internal diversity measures molecules 
active against hERG—a promiscuous target related to 
cardiotoxicity [87]—as diverse as all molecules reported 
active against any kinases, any family A GPCR and more 
diverse than a virtual library designed for diversity. Con-
versely, sphere exclusion diversity measures GDB17 as 
more diverse than GDB13 (which is better distinguished 
at larger sample sizes, see Additional file 1: Figure S3) and 
hERG active molecules as more diverse than single tar-
gets (EGFR and DRD2) but not as diverse as all molecules 
active against any family A GPCR or kinase. Therefore, 
the proposed approach better aligns with chemical intui-
tion regarding the chemical diversity of known libraries. 
Furthermore, this approach yields values in the full range 
of possible values 0–1 (unlike internal diversity which 
mostly lie in a range of ~ 0.7–0.9), which further has a 
direct interpretation as the fraction required to explain 
the chemical space; therefore, a comparative reference 
is not always necessary (unlike internal diversity). How-
ever, the values measured here provide some context 
for sample sizes of 1000 random molecules, which we 
recommend for future use in comparing de novo mol-
ecule diversity. Code to calculate the sphere exclusion 
diversity can be found at our associated GitHub page (see 
“Availability of data and materials”).
DRD2 fingerprint analogues
Further to performance metrics, we also assess the num-
ber of molecular fingerprint analogues generated to 
known DRD2 active molecules. We follow similar meth-
ods as used in [29], converting molecules to Morgan 
fingerprints (radius = 2, nBits = 1024), where analogues 
were considered to be two molecules with a fingerprint 
Tanimoto similarity greater than or equal to 0.4. As 
opposed to [29], we used a smaller Morgan fingerprint 
radius and bit length in line with the other metrics used 
in this work, and did not require molecules to have a 
particular predicted probability of DRD2 activity, as pre-
dicted by the SVM.
Clustering
Molecular clustering was performed on molecules or 
their respective Bemis-Murcko scaffolds [88] using the 
sphere exclusion algorithm [79] as implemented by 
Roger Sayle [80] in RDKit [64]. The sphere radius was 
set at a Tanimoto distance of 0.65 and 0.2 for molecules 
or their respective scaffolds using Morgan fingerprints 
(radius = 2, nBits = 1024). Once resulting sphere cen-
troids had been picked, molecules were assigned to the 
nearest centroid to form a cluster.
Fig. 2 The measured sphere exclusion diversity (SEDiv) (a) and internal diversity (IntDiv) (b) of a randomly sampled 1000 (@1k) subset of a variety 
of virtual libraries and datasets of characterised molecules with activity against particular targets belonging to a target class, or single targets. 
Internal diversity shows counterintuitive behaviour such as, measuring GDB13 as more diverse than GDB17 and hERG active molecules as diverse as 
molecules active against any family A GPCR, any kinase or a virtual library designed towards achieving diversity. Conversely, sphere exclusion diversity 
measures diversity in line with chemical intuition
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Chemical space visualization
In order to further understand the chemistry generated 
by both approaches (and their distribution across chemi-
cal space), Uniform Manifold Approximation and Projec-
tion (UMAP) [89] was performed using both molecular 
fingerprint and physicochemical/property space repre-
sentations, as well as calculating the normalized princi-
pal moments ratio (NPR) [90]. For the former, Morgan 
fingerprints (radius = 2, nBits = 1024, implemented using 
RDKit) of actives (either ‘in’ or ‘all’), Prior, Glide-Agent 
and SVM-Agent molecules were used as input features, 
and the UMAP was calculated using the Jaccard dis-
tance metric with a minimum distance 0. For property 
space, the MolLogP, MolWt, HeavyAtomCount, Num-
HAcceptors, NumHDonors, NumHeteroatoms, NumRo-
tatableBonds, NumAromaticRings, NumAliphaticRings, 
RingCount, TPSA, FractionCSP3, QED [91] and SAscore 
[92] were calculated using RDKit and scaled before input 
to UMAP using default parameters. Lastly, the NPR1 and 
NPR2 were calculated using RDKit after first generating 
3D conformations using the ETKDG method [93].
Structure interaction fingerprints (SIFts)
Structure Interaction Fingerprints (SIFts) [94] were 
calculated on all resulting docked poses in order to 
understand ligand–protein interactions available to the 
generated ligands. This resulted in a 9-element bit vec-
tor for each protein residue, corresponding to non-
exclusive residue interactions. For simplification, we 
converted the non-exclusive 9-element bit vector (com-
prising the possible interactions any contact, backbone, 
sidechain, polar, hydrophobic, hydrogen bond acceptor, 
hydrogen bond donor, aromatic, charged) to exclusive 
residue interactions in a hierarchical manner according 
to the following order: charged hydrogen bond donor/
acceptor, hydrogen bond donor/acceptor, charged, aro-
matic, hydrophobic/polar. For example, a residue initially 
defined as having sidechain, polar, charged and hydro-
gen bond acceptor interactions would be converted to 
charged hydrogen bond acceptor, due to this interaction 
type taking precedent in the above order. This simplifica-
tion was performed to allow for more interpretable (and 
less redundant) subsequent analysis of the interactions 
observed.
Results and discussion
Optimization of SVM‑ and Glide‑Agent‑based scores 
by molecules generated de novo
We investigated whether the Agents were able to opti-
mize the respective properties evaluated by the two scor-
ing functions i.e., predicted probability of DRD2 activity 
based on bioactivity data (‘SVM-Agent’) and DRD2 dock-
ing score (‘Glide-Agent’), the results of which are shown 
in Fig.  3. Both the SVM-Agent and Glide-Agent learn 
to generate molecules with optimized properties, albeit 
at different rates (Fig. 3a and b). Whilst the SVM-Agent 
converges to generating optimal molecules within just a 
few hundred steps, the Glide-Agent only begins to con-
verge after about 2,000 training steps. Crucially, both 
Agents maintain high ratios of valid (> 0.9, Fig.  3c) and 
novel molecules per batch (> 0.9, Fig. 3e). However, from 
just 100 steps onwards, the SVM-Agent starts to generate 
fewer unique molecules than the Glide-Agent (Fig.  3d). 
This suggests overfitting, as the SVM-Agent has maxi-
mally optimized the scoring function and begins to re-
sample molecules that it knows produce a high reward. 
This is further supported by a drop in the diversity of 
sampled molecules and their scaffolds (Fig.  3f–h). We 
also introduce a new diversity metric, sphere exclusion 
diversity (see “Methods”), which indicates that after 200 
steps the chemical space of SVM-Agent de novo mol-
ecules can be explained by less than 10% of the valid and 
unique molecules, while for the Glide-Agent this slowly 
drops to about 20%. In addition, the SVM-Agent shows 
an increased FCD [95] to a held out test set with respect 
to the Glide-Agent (Fig.  3i). This increase in FCD has 
shown to indicate a number of differences [95] to the 
Prior training data for example, ‘drug-likeness’ defined 
by [91] or internal diversity [96]. Beyond the perfor-
mance according to benchmark metrics, and similar to 
Blaschke et al. [29], we investigated the cumulative num-
ber of analogues generated de novo to known DRD2 
active molecules (see Additional file  1: Figure S4). This 
analysis shows that the SVM-Agent generates more ana-
logues (~ 80,000) than the Glide-Agent (~ 25,000), how-
ever, when instead looking at the number of DRD2 active 
molecules with generated analogues, the Glide-Agent 
has analogues to more DRD2 actives (~ 1800) than the 
SVM-Agent (~ 1400). Thus, the SVM-Agent generates 
more analogues per known active, but the Glide-Agent 
generates analogues to a broader range of known actives. 
Together, these results indicate that the Glide-Agent 
maintains better generative metrics throughout training, 
in particular with respect to the uniqueness and general 
diversity of the generated molecules. Also, the Glide-
Agent generates analogues to more known DRD2 active 
molecules, further evidencing increased diversity with 
respect to known DRD2 active molecules.
For any generative model, visual inspection of the 
generated molecules is crucial, both to see whether an 
approach tends to prefer different types of chemistry, 
and to identify any possibly idiosyncratic behaviour. In 
this regard, Fig. 4 displays the centroid of the largest clus-
ters generated during training, as well as the respective 
cluster size. This shows that the chemotypes evolve from 
the Prior differently depending on the scoring function. 
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Overall, both Agents were able to optimize molecules 
towards their respective scoring functions (as shown 
quantitatively in Fig.  3); however, the Glide-Agent does 
so with more diversity (Fig. 3f–h) and with a more similar 
distribution to the training data (Fig. 3i–k).
For further analysis, 10,000 molecules were sampled 
from the unoptimized Prior, the SVM-Agent (trained 
for 500 steps, before significant overfitting occurred), 
and the Glide-Agent (trained for 2000 steps). We calcu-
lated the suite of MOSES metrics [4] on the generated 
molecules (see Additional file 1: Table S1–S3) as well as, 
Scaffold diversity and Scaffold uniqueness and Sphere 
exclusion diversity (see “Methods”). Coinciding with the 
results observed in Fig.  3, the Glide-Agent outperforms 
the SVM-Agent in all metrics except Novelty. Over-
all showing greater diversity of de novo molecules and 
Fig. 3 Generative model performance during optimization for the Glide-Agent (green) and the SVM-Agent (red), calculated every 100 steps. Mean 
optimization of scores—docking score and predicted probability of activity—are shown in (a) and (b) respectively, as well as the 95% confidence 
interval. Additional metrics shown are (c) validity, (d) uniqueness, (e) novelty, (f) internal diversity, (g) scaffold diversity, (h) sphere exclusion diversity, 
(i) Fréchet ChemNet Distance, (j) single nearest neighbour similarity and (k) fragment similarity. As the most important observation, the SVM-Agent 
reaches very high scores much more quickly, which comes at the cost of a significant reduction in uniqueness and diversity, when compared to the 
Glide-Agent. For definitions and detailed discussion see main text
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similarity to the training data (whilst still optimizing the 
docking score).
Next, we sought to better understand the extent to 
which the docking score could be optimized using 
our protocol, relative to known DRD2 active mol-
ecules. All molecules were docked, and their docking 
scores compared to the active, inactive and random 
reference dataset, the results of which are shown in 
Fig. 5a. The actives and inactives are further split into 
‘all’ molecules extracted from ExCAPE-DB and mol-
ecules ‘in’ a similar chemical space as imposed by the 
same filters applied to the training data. The docking 
score distribution of the Glide-Agent de novo mol-
ecules (μ = − 8.05, σ = 0.95) is significantly enriched 
(one-tail t-test: adjusted p < 0.05) over unoptimized 
Prior molecules (μ = − 6.17, σ = 1.02) and importantly 
also over previously known DRD2 active molecules 
(μ = -7.45, σ = 1.01)(one-tail t-test: adjusted p < 0.05), 
especially those after filtering to impose similar chem-
ical space restrictions (μ = − 6.96, σ = 0.74)(one-tail 
t-test: adjusted p < 0.05). In other words, the Glide-
Agent de novo molecules are predicted to be often as 
active, and on average even more active, than known 
DRD2 active molecules according to the Glide dock-
ing protocol. If the precision for selecting active mol-
ecules for retrospective docking at a score threshold 
of − 8.5 (see “Methods”) translates also prospectively 
to de novo generated molecules, 32.70% percent of 
the Glide-Agent de novo molecules are predicted to 
be active against DRD2 (that is with a dose–response 
value lower than 10 µM), compared to 19.98% percent 
of SVM-Agent de novo molecules and 0.54% percent 
of Prior de novo molecules (which is relatively close 
to experimental hit rates that would be expected by 
chance alone, e.g. [97] which had an experimental hit 
rate against DRD2 of ~0.6%). Interestingly, the SVM-
Agent de novo molecules also exhibit a significant 
enrichment (one-tail t-test: adjusted p < 0.05) in dock-
ing score distribution (μ = − 7.85, σ = 0.80) beyond 
known DRD2 active molecules, although to a lesser 
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Fig. 4 Chemotype evolution during training, comparing the SVM-Agent and the Glide-Agent. Molecules were sampled during training at the start 
and after 0, 1000, 2000 and 3000 steps (at the end of training). Molecules in each batch were clustered and the centroids of the three largest clusters 
are shown here, alongside respective cluster size (CS). This visualizes the difference in topology and chemotype between the two approaches
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extent. This docking score distribution enrichment is 
hypothesized to be a factor of generating similar de 
novo chemistry to known DRD2 actives and hence, a 
docking score enrichment is observed. However, the 
improvement over known actives seen in Fig.  5a may 
also be due to an element of randomness, as Renz et al. 
observed different chemical space occupation for inde-
pendent runs with similar models [27]. Furthermore, 
a previous run we conducted resulted in a smaller 
enrichment for the SVM-Agent but an almost identi-
cal enrichment for the Glide-Agent (data not shown). 
We also compared the predicted probability of DRD2 
activity according the SVM (Fig.  5b) for all reference 
datasets. This shows that most known DRD2 actives 
and the SVM-Agent de novo molecules are predicted 
active with high probability (0.9–1.0). Unlike docking, 
which predicts SVM-Agent molecules to be equally as, 
or more active than known DRD2 active molecules, the 
SVM does not predict many Glide-Agent molecules to 
be active (about 75% with a low predicted probabil-
ity of 0–0.1). Due to the limitations of such machine 
learning models discussed in the Introduction, we 
believe this could be evidence of a limited applicability 
domain. This is supported by the greater single nearest 
neighbour similarity of the SVM-Agent de novo mole-
cules to DRD2 actives that were used by train the SVM 
model by [7] (see Fig.  7 and Additional file  1: Figure 
S5). Overall, we can conclude that the docking score of 
de novo molecules can generally be optimized by our 
Glide-based agent, and this is true even beyond the 
scores of known active molecules.
Overlap analysis of molecules generated de novo 
compared to known active and inactive molecules
To assess recovery of known active molecules we iden-
tified whether any of the canonical SMILES produced 
by either Agent matches those of known DRD2 active 
molecules. The number of recovered molecules across 
ten samples of 10,000 molecules was converted into the 
probability of recovery (see Table 1) (based on valid and 
unique molecules generated). It is worth noting that 
the Prior has an inherent bias towards generating inac-
tive molecules over active molecules, where we quantify 
the bias simply as the probability of generating a known 
active molecule over the probability of generating a 
known inactive molecule. This translates as the Prior 
being 0.002 times as likely to generate an active mole-
cule compared to an inactive (which is partly also due to 
removing known DRD2 active molecules from the train-
ing data). When considering recovery of ‘all’ extracted 
DRD2 actives and inactives, both Agents are still biased 
towards generating inactive molecules; however, the 
Prior bias is improved 95-fold towards generating active 
molecules by the SVM-Agent. This bias shift is predomi-
nantly attributable to the SVM-Agent’s ability to avoid 
recovering known inactive molecules (approx. half the 
probability than the Glide-Agent), whereas the probabil-
ity of recovering known active molecules is more compa-
rable between the Glide- and SVM-Agents (63 ×  10–6 vs 
79 ×  10–6, respectively). It is important to consider that 
Glide docking does not incorporate any prior knowledge 
of known DRD2 active and inactive molecules (unlike the 
SVM), and therefore the Glide-Agent is able to learn to 
Fig. 5 Docking scores (a) and predicted probability of DRD2 activity (b) of molecules generated de novo using the Prior, the SVM-Agent and the 
Glide-Agent, compared to the active, inactive, and random reference datasets. The more negative the docking score, the better it is predicted to 
bind. The Glide-Agent generated molecules have the best docking score distribution, more so than known DRD2 active molecules, whilst the 
SVM-Agent generated molecule distribution is more similar to known DRD2 active molecules. The SVM-Agent molecules and known DRD2 actives 
score most highly according to the SVM, comparatively, the Glide-Agent molecules do not
Page 12 of 20Thomas et al. J Cheminform           (2021) 13:39 
recover known active molecules (and improve the Prior 
bias 40-fold) from the information of the scoring func-
tion alone. Interestingly, of the single sample of 10,000 
molecules investigated throughout this work, there are 
no recovered active molecules in common between the 
Agents, and just three in total (see Additional file 1: Fig-
ure S6), further underlining their divergent behaviour. 
In summary, both Agents can similarly recover known 
DRD2 active molecules, however, the SVM-Agent is bet-
ter at not generating known inactives and thus provide 
different types of molecules generated de novo as a result.
Similarity analysis of molecules generated de novo 
to known active and inactive molecules
We first repeated the analysis conducted during train-
ing, investigating the number of analogues to known 
DRD2 active compounds as in [29]. Similar to the results 
observed during training, Table 2 shows the SVM-Agent 
sample contains a higher fraction of molecules consid-
ered fingerprint analogues to DRD2 actives (both to 
actives ‘in’ a similar chemical space and ‘all’ extracted). 
Furthermore, both Agent samples contain a higher frac-
tion of analogues to DRD2 actives than inactive mole-
cules (which one would expect to be relatively high based 
on the chemical series nature of drug design). Although 
the Glide-Agent generates analogues to a higher frac-
tion of DRD2 actives, indicating that the higher diversity 
observed (see Additional file 1: Table S2) is relevant with 
respect to active chemistry. In addition, the DRD2 actives 
with analogues generated differed depending on the Prior 
or Agent (see Additional file  1: Figure S7), evidencing 
complementary behaviour with respect to identifying 
similar molecules to known actives.
We also investigated how similar the de novo gener-
ated molecules were to known DRD2 active molecules 
and/or each other. The known DRD2 active mol-
ecules were clustered together with the Prior, Glide- 
and SVM-Agent de novo molecules. Each cluster was 
then analysed to identify to which dataset each of its 
members belonged (similar to [98]). Figure  6 shows 
the results of this analysis as a Venn diagram for both 
entire molecules (Fig.  6a) and their respective Bemis-
Murcko scaffolds (Fig.  6b). This analysis shows more 
clusters-105—are shared between known active DRD2 
molecules and the Glide-Agent, compared to the 
overlap of known active DRD2 ligands with the SVM-
Agent, where this number is 95. This is also observed 
when clusters are calculated based on scaffolds (49 vs 
39 respectively). To qualitatively assess cluster behav-
iour, examples of clusters and structures are shown 
in Additional file  1: Figure S8–S9. Overall, both the 
Glide-Agent and SVM-Agent share a relatively similar 
number of clusters (i.e. ‘chemical space pockets’) with 
known DRD2 actives, but which precise clusters are 
shared differs largely between both Agents.
Table 1 Probability of recovering known DRD2 active and inactive molecules
The reported probability values are the mean (and standard deviation) across ten samples of 10,000 de novo molecules drawn from the model. The Glide- and SVM-
Agent have a similar probability of recovering known active molecules, therefore the SVM-Agent bias towards generating active molecules over inactivate molecules 
is mostly driven by the lower probability of generating inactive molecules
Origin of dataset Probability of generating 
active molecule (×  10−6)
Probability of generating inactive 
molecule (×  10−6)
Active bias (fold change from 
Prior)
Active DRD2 chemical space 
relative to training data
In All In All In All
Prior 10 (30) 10 (30) 5055 (604) 5957 (495) 0.002 (1) 0.002 (1)
Glide-Agent 11 (32) 63 (84) 422 (125) 917 (175) 0.025 (12.5) 0.069 (40.6)
SVM-Agent 34 (72) 79 (72) 256 (124) 486 (168) 0.130 (64.9) 0.163 (95.7)
Table 2 Fraction of molecules that are fingerprint analogues to 
DRD2 active molecules and respective fraction of DRD2 active 
molecules with analogues
The SVM-Agent generates more analogues to known actives, however, the 
Glide-Agent generates analogues to more known actives, demonstrating a 
greater coverage of known active space
Origin of dataset Fraction of 
molecules that are 
analogues to DRD2 
actives
Fraction of DRD2 
actives with 
analogues
DRD2 chemical space 
relative to training data
In All In All
Inactive (in) 0.020 0.089 0.197 0.116
Inactive (all) 0.025 0.102 0.242 0.116
Train 0.020 0.071 0.225 0.109
Random 0.024 0.075 0.313 0.120
Prior 0.021 0.071 0.220 0.110
Glide-Agent 0.051 0.124 0.268 0.105
SVM-Agent 0.179 0.563 0.237 0.102
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Novelty of de novo molecules relative to known DRD2 
active molecules
Similarity comparisons of de novo molecules to known 
molecules with desirable properties can provide a 
measure of confidence that a model is in the correct 
chemical space. However, prospective use case ulti-
mately requires structural novelty to known com-
pounds with activity against the same biological target. 
Fig. 6 Chemical space overlap between the Prior, SVM- and Glide-Agents with all DRD2 ligands extracted from ExCAPE-DB. Broader clusters (a) 
were defined by clustering molecules with a Morgan fingerprint Tanimoto similarity to a centroid of 0.35 or greater, while narrower clusters (b) were 
defined by clustering molecules on their Bemis-Murcko scaffold Morgan fingerprint Tanimoto similarity to a centroid of 0.8 or greater (examples 
shown in Additional file 1: Figure S8-9). Numbers specify the number of clusters with at least one member belonging to an annotated dataset. For 
example, there are 23 clusters (a) where each cluster has at least one member belonging to DRD2 actives and Glide-Agent molecules. Both the 
Glide-Agent and SVM-Agent share clusters with known DRD2 active molecules
Fig. 7 Kernel density estimates of the bivariate distribution of docking score and single nearest neighbour similarity to known DRD2 active 
molecules. The Glide-Agent distribution contains a shoulder with lower (better) docking scores at lower similarity to known actives than the 
SVM-Agent and Prior de novo molecules
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Figure  7 shows that the Glide-Agent generated mol-
ecules that have enriched docking scores below the 
retrospective threshold of − 8.5 also have lower single 
nearest neighbour similarity to known DRD2 active 
molecules than the SVM-Agent and Prior molecules. 
Therefore, the Glide-Agent molecules are not only 
predicted more active but are also more novel with 
respect to known actives than the SVM-Agent mol-
ecules. This could prove very important in the early 
stages of hit discovery.
Differences in chemical substructural and physicochemical 
property space between Glide‑ and SVM‑Agent generated 
molecules
To further understand the chemical differences between 
the molecules generated by the Glide- and SVM-Agent 
Uniform Manifold Approximation and Projection 
(UMAP) [89] was used to reduce the molecular finger-
print and physicochemical and property descriptor-
based representations of chemical structures into two 
dimensions for visualization purposes. Furthermore, we 
investigate the 3D shape of molecules by looking at the 
normalized principal moments ratio (NPR) [90]. Figure 8 
Fig. 8 Chemical space representation of (a) molecular fingerprints and (b) physicochemical descriptors and (c) 3D space via moments of inertia. 
The plots show the calculated kernel density estimate with 100 randomly drawn samples overlayed. UMAP representation (a–b) was calculated 
for known active DRD2 ligands with filters applied to impose a similar chemical space, as well as the chemical structures associated with the Prior, 
Glide- and SVM-Agents. The Agents occupy complementary regions of topological space (a), physicochemical property space (b) and slightly 3D 
space (c) (where the Glide-Agent stretches slightly more towards spherical and the SVM-Agent slightly more towards disc shape)
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shows the two-dimensional embedded space of known 
DRD2 active molecules (filters applied to impose simi-
lar chemical space), as well as Prior, Glide- and SVM-
Agent generated de novo molecules. When molecules 
are defined by their molecular fingerprints (Fig.  8a), 
the Glide- and SVM-Agents occupy different regions of 
chemical space, of which neither have significant distri-
bution overlap with known DRD2 active molecules. The 
SVM-Agent de novo molecules are more distinct from 
the Prior molecules, albeit still restricted by nature of 
the optimization function and inclusion of the Prior 
likelihood. In Fig.  8b, where molecules are defined by 
physicochemical and property descriptors, the Prior 
and Glide-Agent generated de novo molecules occupy a 
complementary and more diverse area of property space 
than SVM-Agent molecules. By annotating this embed-
ding, it can be seen that the clustering predominantly 
correlates with the number of hydrogen bond donors and 
number of aromatic/aliphatic rings (see Additional file 1: 
Figure S10). Figure  8c shows a smaller difference in the 
distribution of 3D shapes between the datasets, again the 
models show slight complementary behaviour where the 
Glide-Agent distribution stretches slightly more towards 
spherical shapes and SVM-Agent slightly more towards 
disk shapes, although this difference is minor. The obser-
vations seen here are similar when considering ‘all’ DRD2 
actives extracted from ExCAPE-DB (see Additional file 1: 
Figure S11), however, the representation is compressed 
due to larger and more distinct molecules seen in the 
active set. This analysis further corroborates, in a visual 
manner, the chemical differences between the structure- 
and ligand-based approaches, and the additional physico-
chemical diversity obtained by the Glide-Agent, which 
is not biased towards the properties of known bioactive 
molecules. For further exploration, we refer readers to 
Additional file  2 that allows exploration and visualiza-
tion of chemical structures associated with embedded 
molecules.
Characterization of de novo ligand chemistry
In order to understand the occupation of chemical 
space at the end of the runs on a ligand structural level, 
the molecules in each dataset were clustered accord-
ing to their Bemis-Murcko scaffolds [88] which resulted 
in more stringent clusters more akin to chemical series. 
When filtering out clusters with less than 10 members 
(i.e., smaller ‘virtual series’), the Glide-Agent set con-
tained more clusters with better mean docking scores 
than all other datasets (see Additional file 1: Figure S12). 
More specifically, the Glide-Agent set contains 30 such 
clusters with a mean docking score less than the previ-
ously defined threshold of -8.5, compared to just six 
clusters of DRD2 actives, 22 in SVM-Agent set and zero 
clusters in the Prior set. In this way, the Glide-agent was 
able to identify chemical series that dock consistently 
well; something that is less frequently observed for the 
SVM-Agent or even known actives, and non-existent 
for Prior de novo molecules. This behaviour is analogous 
to the identification of bioactive chemical series in an 
experimental screening, where additional confidence is 
provided that the compounds identified are indeed true 
positive hits, as opposed to singletons, as false positives 
can occur due to experimental error (or, in the current 
case, idiosyncratic behaviour of the scoring function). 
Alternatively, it could be argued that the scoring func-
tion is not sensitive enough to identify subtle differences 
in ligand chemistry that result in inactivity, commonly 
referred to as activity cliffs i.e. strong nonadditivity in 
structure–activity relationships. However, one study 
investigated strong nonadditivity between matched 
molecular pair cycles with respective structural data [99], 
and identified that in 10 out of 15 possible cases there 
was a structural explaination, such as, complete rear-
rangement of binding mode or substituent interactions 
causing nonadditivity. Therefore, we theorize that scoring 
functions that take into account structural information 
may better account for nonadditivity than purely ligand-
based ones.
Figure 9 shows the cluster centroids of the two larg-
est and the two best-scoring clusters from each respec-
tive dataset (minimum of 10 clusters). Typical known 
DRD2 active molecules are ‘capped’ by mono- or bicy-
clic systems which are linked by an aliphatic chain that 
usually (but not exclusively) contains a piperidine/
piperazine moiety. This chemotype is not well reca-
pitulated by the Prior molecules as it is not optimized 
towards DRD2 bioactivity in any way. The Glide-Agent 
on the other hand learns to mostly cap the molecules 
with mono- or bicyclic systems, but it does not gener-
ate the piperidine/piperazine moiety in the compounds 
shown here. Likewise, the SVM-Agent also learns to 
cap the molecules in this manner, and the highest-
scoring cluster centroids also contain aliphatic chains 
with rings in the linker, although commonly pyrroli-
dine and diazepane, as opposed to piperidine or pip-
erazine. At least one protonatable nitrogen is common 
across most structures (from either origin), mostly 
located in the aliphatic linker. Somewhat concern-
ingly, some of the example structures shown in Fig.  9 
have the potential to be di-cationic. This can be unde-
sirable from a drug discovery perspective due to low 
logD and thus, potential implications with high clear-
ance and low permeability. We investigated this fur-
ther, and found (see Additional file 1: Figure S13) that 
the distribution of formal charge (as assigned by our 
protocol) for the Glide-Agent closely resembles that of 
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known DRD2 actives (predominantly + 1). In fact, the 
SVM-Agent is slightly shifted towards containing more 
di-cationic molecules (~ 30%), despite the SVM being 
trained on known DRD2 actives (< 10% di-cationic). 
Furthermore, the Glide-Agent was able to improve the 
docking score distribution from the Prior for all formal 
charges (see Additional file 1: Figure S14). Overall, we 
can conclude that we did not find any evidence that di-
cationic molecules were preferred by the Glide-Agent 
due to any biases in the scoring method employed.
One crucial requirement of de novo molecules for 
practical use is synthetic accessability. In this work, we 
find that both Prior and Agent generated molecules 
closely inherit the SAscore distribution of the ZINC 
training dataset (see Additional file  1: Figure S15) 
which is likely due to the inclusion of Prior likelihood 
in the optimization function [7]. Despite the fact that 
goal-directed optimization tasks have previously led 
to worse syntheizability [100]. Furthermore, we don’t 
find the need to add proxy functions such as SAscore 
or QED to the optimization function (unlike recent 
approaches [101, 102]) due to stringent filtering of the 
training dataset, of which the model does not deviate 
too much.
Understanding method behaviour at the ligand–protein 
interaction level
In order to interpret the interactions formed by de novo 
ligands originating from the different methods also at 
the ligand–protein interaction level, the docked poses 
of the two highest-scoring and the two most common 
cluster centroids from Fig. 9 were generated (Fig. 10). As 
expected, known DRD2 ligands form a hydrogen-bond 
interaction with  D1143x32, a highly conserved residue in 
aminergic receptors that has been shown to be crucial 
for ligand binding [66, 67]. This reproduction of charge 
interactions with  D1143x32 can be observed in the high-
est-scoring molecules across all datasets, while in this 
instance, the Glide-Agent molecules show more distinct 
 D1143x32 interaction types (e.g. also hydroxyl interac-
tions, Fig. 10) and vectors.
To understand the protein–ligand interactions present 
in the datasets on a broader scale, Structural Interac-
tion Fingerprints (SIFts) [94] were calculated. Figure  11 
summarises the changes in these interactions observed 
relative to the Prior (as a baseline) visually. All DRD2 
binders extracted from ExCAPE-DB tend to form more 
interactions with residues located higher in the pocket 
(towards the extracellular surface). While the Glide-
Agent molecules more often satisfy interactions deeper 











































































































































Fig. 9 Most common and highest-scoring chemotypes of two most highly populated and the two highest-scoring clusters for each individual 
dataset, annotated by cluster size (CS) and mean cluster docking score (DS). The Glide- and SVM-Agent generated molecules show similar mono- or 
bicyclic capping of molecules as known DRD2 active molecules
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in the pocket and less often shallower ones (dissimilar to 
known DRD2 active molecules). Likewise, SVM-Agent 
molecules more often form interactions with residues 
deeper in the pocket. This is likely partially due to the 
restriction in molecular weight imposed by the ZINC 
subset used to train the Prior, which selects molecules 
with a molecular weight between 250 and 350 Daltons, 
subsequently biasing de novo molecule generation to 
a similar molecular weight range. Furthermore, when 
only considering actives with the same filters applied 
(i.e., molecular weight 250–350 Da) there are few residue 
interaction differences compared to Prior generated mol-
ecules. Surprisingly, the Glide-Agent de novo molecules 
have a lower molecular weight distribution (see Addi-
tional file 1: Figure S15), showing that in the current case 
smaller molecules are favourable for optimizing docking 
score, resulting in increased virtual ligand efficiency. This 
is in contrast to previous publications, which frequently 
found that larger molecules are favoured by many scoring 
functions [103, 104]. Although there is no relative change 
in the sum of interactions satisfied with  D1143x32 (despite 
its crucial role in ligand binding), the ratio of interac-
tion type changes between datasets. The Glide-Agent 
de novo dataset has a higher fraction of charged hydro-
gen-bonding interactions (~ 0.75) than the Prior (~ 0.4), 
SVM-Agent (~ 0.6) and known DRD2 actives (~ 0.4–0.5), 
where all other interactions are comprised of charged 
non-hydrogen-bonding interactions (see Additional 
file 1: Figure S16). In addition, charged hydrogen-bond-
ing interactions were associated with a better docking 
Fig. 10 Docked pose of the cluster centroids of the two most common and highest-scoring chemotypes with DRD2. The highest-ranked ligand in 
both cases is displayed with sticks (green), and the second-highest ligand with lines (cyan). The Glide- and SVM-Agent examples both reproduce 
crucial  D1143x32 interactions
Fig. 11 Change in the frequency of DRD2 residue interactions relative to Prior de novo molecules according to Structural Interaction Fingerprints 
(SIFTs). Green indicates a relative increase equal to or more than 10% than Prior molecules, while red indicates a decrease less than or equal to 10%
Page 18 of 20Thomas et al. J Cheminform           (2021) 13:39 
score distribution than charged non-hydrogen-bonding 
interactions (see Additional file 1: Figure S17), an associ-
ation which is also experimentally confirmed with higher 
affinity [105]. In summary, Glide-Agent optimized de 
novo molecules satisfy more charged hydrogen-bonding 
interactions with  D1143x32 and generate lower molecular 
weight molecules than known DRD2 active molecules 
and SVM-Agent de novo molecules.
Conclusions
In this work we integrated a generative molecular de 
novo algorithm with ligand–protein docking and com-
pared the results obtained to a ligand-based scoring func-
tion. We show on a commonly used benchmark dataset 
for the Dopamine D2 receptor that this approach results 
in chemically sensible molecules, which can improve 
docking scores beyond that of known receptor ligands, 
while exhibiting increased physicochemical diversity 
compared to using the ligand-based scoring function. 
The work presented here demonstrates the use of deep 
generative models in settings also where no ligand data 
is available, or novelty is of particular interest (provided 
an X-ray crystal structure or a suitable homology model 
of the target is available). Further validation on a variety 
of protein targets is both required and currently ongoing. 
Moreover, this work only investigates the optimization 
of the Glide docking score and does not validate alterna-
tive structure-based scoring functions. While we expect 
other scoring functions to be equally optimizable, the 
resulting de novo chemistry may differ as a function of 
other forcefield implementations and/or scoring func-
tion definitions such as changes in interaction terms, for 
example. Preliminary analysis (data not shown) suggests 
that this is the case when using Smina as opposed to 
Glide. Future work is also intended to further investigate 
the impact of incorporating prior structural knowledge, 
such as particular water/residue interactions that can 
affect selectivity.
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